{
    "clinical_study": {
        "@rank": "13109", 
        "arm_group": [
            {
                "arm_group_label": "MK-8237 6 DU", 
                "arm_group_type": "Experimental", 
                "description": "MK-8237 6 DU rapidly dissolving tablet administered sublingually once daily for 28 days"
            }, 
            {
                "arm_group_label": "MK-8237 12 DU", 
                "arm_group_type": "Experimental", 
                "description": "MK-8237 12 DU rapidly dissolving tablet administered sublingually once daily for 28 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo rapidly dissolving tablet administered sublingually once daily for 28 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety of two doses (6 Development Units [DU]\n      and 12 DU) of MK-8237 sublingual tablets compared to Placebo in adolescents with house dust\n      mite-induced allergic rhinitis/rhinoconjunctivitis.\n\n      Study Hypothesis:\n\n      At least one dose of MK-8237 sublingual tablet is safe and well-tolerated in adolescents\n      with house dust mite-induced allergic rhinitis/rhinoconjunctivitis."
        }, 
        "brief_title": "Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Rhinitis, Allergic, Perennial", 
            "Rhinitis, Allergic, Nonseasonal"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis", 
                "Rhinitis, Allergic, Perennial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  History of physician-diagnosed allergic rhinitis/rhinoconjunctivitis to house dust of\n             at least 6 months duration (with or without asthma)\n\n          -  History of controlled asthma for the prior 1 month if participant has asthma, defined\n             by not exceeding 2 days of symptoms per week; not more than 2 days of albuterol/short\n             acting beta-agonist [SABA] use per week; and not wakening more than twice a month at\n             night due to asthma symptoms\n\n          -  Agrees to remain abstinent or use (or have their partner use) 2 acceptable methods of\n             birth control from screening and through the duration of the study\n\n        Exclusion Criteria:\n\n          -  Unable to meet medication washout requirements\n\n          -  History of chronic urticaria and/or chronic angioedema within prior 2 years\n\n          -  History of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy due\n             to an unknown cause or to an inhalant allergen\n\n          -  Unstable, uncontrolled or severe asthma, or has experienced a life-threatening asthma\n             attack or an occurrence of any clinical deterioration of asthma that resulted in\n             emergency treatment, hospitalization due to asthma, or treatment with systemic\n             corticosteroids (but allowing SABAs) at any time within prior 3 months\n\n          -  History of chronic sinusitis during within prior 2 years\n\n          -  Pregnant or breast-feeding, or expecting to conceive within the projected duration of\n             the study\n\n          -  Known history of allergy, hypersensitivity or intolerance to investigational\n             medicinal products (except for D. pteronyssinus and/or D. farinae) or self-injectable\n             epinephrine\n\n          -  Business or personal relationship with investigational site personnel or Sponsor who\n             is directly involved with the conduct of the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "195", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01678807", 
            "org_study_id": "8237-008", 
            "secondary_id": "MK-8237-008"
        }, 
        "intervention": [
            {
                "arm_group_label": "MK-8237 6 DU", 
                "intervention_name": "MK-8237 6 DU", 
                "intervention_type": "Biological", 
                "other_name": "SCH 900237"
            }, 
            {
                "arm_group_label": "MK-8237 12 DU", 
                "intervention_name": "MK-8237 12 DU", 
                "intervention_type": "Biological", 
                "other_name": "SCH 900237"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 20, 2013", 
        "number_of_arms": "3", 
        "official_title": "Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (Protocol 008)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of Participants Who Experience At Least One Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 42 days"
            }, 
            {
                "measure": "Percentage of Participants Who Discontinue Study Drug Due to an Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days"
            }
        ], 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01678807"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}